GlassScriptPhysician profile
Luis A Casas
NPI 1588642326
$943.93
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $124 · 2021: $159 · 2022: $346 · 2023: $21.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $21.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $195.48 | 2019-2020 | |
| Novo Nordisk INC | $180.37 | 2020-2022 | |
| Pfizer INC. | $111.86 | 2019-2022 | |
| Daiichi Sankyo INC. | $86.05 | 2021-2022 | |
| Lilly USA, LLC | $72.52 | 2022-2023 | Mounjaro |
| Sanofi Pasteur INC. | $49.42 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $36.71 | 2019-2022 | |
| Glaxosmithkline, LLC. | $27.17 | 2021 | |
| Allergan, INC. | $25.02 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.54 | 2019 | |
| Medtronic USA, INC. | $24.51 | 2019-2020 | |
| Bausch Health US, LLC | $23.85 | 2022 | |
| Endo Pharmaceuticals INC. | $19.26 | 2022 | |
| Seqirus USA INC | $19.03 | 2022 | |
| Amarin Pharma, INC. | $18.14 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $16.07 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Casas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.